ロード中...
Gardos pathway to sickle cell therapies?
In this issue of Blood, Ataga and colleagues report that treatment of sickle cell disease patients with senicapoc, a Gardos channel inhibitor, reduces the number of dehydrated cells, increases hemoglobin levels, and diminishes hemolysis.
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2008
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2288713/ https://ncbi.nlm.nih.gov/pubmed/18434967 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-01-135350 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|